Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9790069rdf:typepubmed:Citationlld:pubmed
pubmed-article:9790069lifeskim:mentionsumls-concept:C0020099lld:lifeskim
pubmed-article:9790069lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:9790069lifeskim:mentionsumls-concept:C0017278lld:lifeskim
pubmed-article:9790069lifeskim:mentionsumls-concept:C1422036lld:lifeskim
pubmed-article:9790069pubmed:issue4lld:pubmed
pubmed-article:9790069pubmed:dateCreated1998-12-31lld:pubmed
pubmed-article:9790069pubmed:abstractTextA monoclonal antibody (MAb), gp21-34, specifically reactive with human T-lymphotropic virus type-II (HTLV-II) transmembranous envelope glycoprotein (p20E) was developed by immunization with a recombinant protein fused with thioredoxin moiety at the N-terminal portion. This MAb, which belongs to the IgG1 kappa subclass, reacted with HTLV-II infected cell lines (TON-1, C3-44, and Si-IIA) by IFA, but not with HTLV-I infected cell lines (TCL-Kan and MT-2). By Western blot analysis, this MAb reacted with p20E of HTLV-II lysates but not with HTLV-I lysates. Some epitope analyses with synthetic peptides were carried out to look for a plausible linear epitope in the C-terminal region of p20E.lld:pubmed
pubmed-article:9790069pubmed:languageenglld:pubmed
pubmed-article:9790069pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:citationSubsetIMlld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9790069pubmed:statusMEDLINElld:pubmed
pubmed-article:9790069pubmed:monthAuglld:pubmed
pubmed-article:9790069pubmed:issn0272-457Xlld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:HondaHHlld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:ItoSSlld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:FujiiNNlld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:UenoEElld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:MiyagawaEElld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:YoshikiAAlld:pubmed
pubmed-article:9790069pubmed:authorpubmed-author:KuraneSSlld:pubmed
pubmed-article:9790069pubmed:issnTypePrintlld:pubmed
pubmed-article:9790069pubmed:volume17lld:pubmed
pubmed-article:9790069pubmed:ownerNLMlld:pubmed
pubmed-article:9790069pubmed:authorsCompleteYlld:pubmed
pubmed-article:9790069pubmed:pagination347-54lld:pubmed
pubmed-article:9790069pubmed:dateRevised2003-11-19lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:meshHeadingpubmed-meshheading:9790069-...lld:pubmed
pubmed-article:9790069pubmed:year1998lld:pubmed
pubmed-article:9790069pubmed:articleTitleEstablishment of monoclonal antibody, gp21-34, against HTLV-II envelope protein (p20E).lld:pubmed
pubmed-article:9790069pubmed:affiliationUbe Research Laboratory, Fujirebio, Inc., Yoshiwa Ube, Yamaguchi, Japan.lld:pubmed
pubmed-article:9790069pubmed:publicationTypeJournal Articlelld:pubmed